Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1803 results
November 2021
-
The art of drug design in a technological age
Novartis is collaborating with Microsoft to apply machine learning to medicinal chemistry — part of an effort to leverage AI to bring treatments to patients more efficiently.
-
Stopping this coronavirus – and the next one
Inside the hunt for new antivirals to combat the current pandemic and to prepare for future ones.
-
Media ReleaseNovartis presents positive Phase III results for Cosentyx® in children with active enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) at ACR 2021Treatment with Cosentyx® (secukinumab) resulted in a 72% reduced flare risk versus placebo, with improvement in disease activity over two years across both enthesitis-related arthritis (ERA) and…
-
Media ReleaseNovartis announces new publication in Cephalalgia of data showcasing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine preventionHER-MES, a Phase IV study, is the first and only randomized, double blind, head-to-head study that compares an antibody targeting the CGRP pathway, Aimovig® (erenumab), with an oral prophylactic…
-
Media ReleaseLeqvio®* (inclisiran) reduced LDL-C in people who are overweight or obeseRegardless of body mass index (BMI), Leqvio provided sustained and effective LDL-C reduction of ~50% with two doses a year**, according to pooled analysis of three Phase III studies 1Being overweight…
-
Solving the puzzle of immunotherapy
From an eccentric idea to a revolution in medicine – the history of immunotherapy and a peek into its future.
-
Media ReleaseNovartis iptacopan meets primary endpoints in Phase II study in rare kidney disease C3 glomerulopathy (C3G)Statistically significant and clinically important reductions in proteinuria were achieved for the primary endpoint for patients with C3G1 Additionally, statistically significant reduction in C3…
-
Media ReleaseNew data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolioNew longer-term efficacy and safety data from pivotal Phase III ASCEMBL study for recently US-approved Scemblix® (asciminib) in patients with PH+ CML-CPEarly findings from YTB323 and PHE885 CAR-T…
-
Featured NewsRaising awareness of prostate cancer during Movember
Despite advancements in care, prostate cancer is one of the most frequently diagnosed cancers around the world. This Movember, we’re focused on raising awareness of prostate cancer.
-
Breaking down barriers for patients with sickle cell disease
One patient’s story reveals the hidden obstacles to better health – and opportunities to help clear them.
-
Key ReleaseNovartis to sell its Roche stake in a bilateral transaction to RocheAd hoc announcement pursuant to Art. 53 LR Novartis and Roche agree a bilateral transaction for the sale of Roche bearer shares held by Novartis for a total consideration of USD 20.7 billion…
-
Key ReleaseNovartis verkauft ihre Roche-Beteiligung in einer bilateralen Transaktion an RocheAd-hoc-Mitteilung gemäss Art. 53 KR Novartis und Roche vereinbaren bilaterale Transaktion zum Verkauf von Roche-Inhaberaktien im Besitz von Novartis zu einem Gesamtpreis von USD 20,7 Mrd. Der…
Pagination
- ‹ Previous page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- …
- 151
- › Next page